NCT07175376 Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
| NCT ID | NCT07175376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2026-03-16 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.
Eligibility Criteria
Inclusion Criteria: Patients with cancer: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 65 years at the time of enrollment. * Planned to initiate an outpatient chemotherapy regimen for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent. * eFI pre-frail or frail status (available in EHR) within 30 days before enrollment. * Ability to read and understand the English language Providers: * Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment. Exclusion Criteria: Patients: * Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator. * Chemotherapy planned at a facility outside the Atrium Health system. * Currently receiving chemotherapy
Contact & Investigator
Heidi Klepin, MD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT07175376 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07175376 currently recruiting?
Yes, NCT07175376 is actively recruiting participants. Contact the research team at james.morgan@advocatehealth.org for enrollment information.
Where is the NCT07175376 trial being conducted?
This trial is being conducted at Charlotte, United States, Winston-Salem, United States.
Who is sponsoring the NCT07175376 clinical trial?
NCT07175376 is sponsored by Wake Forest University Health Sciences. The principal investigator is Heidi Klepin, MD at Wake Forest University Health Sciences. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.